Yasuyuki Suzuki (1), Kazuhiro Goto (1), Atsushi Ishige (1), Yasuhiro
Komatsu (1) and Junzo Kamei (2)
(1) Kampo and Pharmacognosy Laboratories, Tsumura & Co., Ami-machi, Inashiki-gun, Ibaraki 300-1192, Japan
(2) Department of Pathophysiology & Therapeutics, Faculty of Pharmaceutical Sciences, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan
Abstract: We evaluated the effects of Gosha-jinki-gan on platelet aggregation in streptozotocin-induced diabetic rats. Enhanced ADP (2 microM)-induced aggregation of platelets obtained from diabetic rats was inhibited by a single treatment with Gosha-jinki-gan (0.3, 1.5 g/kg, p.o.). The anti-platelet aggregatory effect of Gosha-jinki-gan (1.5 g/kg, p.o.) was attenuated by simultaneous administration of atropine (1 mg/kg, i.p.) and was abolished by combination of atropine with Hoe 140 (250 microg/kg x 2, i.p.), a bradykinin B2 receptor antagonist or L-NAME (10 mg/kg, i.p.), an inhibitor of nitric oxide-synthase. These results suggested that Gosha-jinki-gan could improve platelet aggregation in diabetes through increased production of nitric oxide via bradykinin B2-receptors and muscarinic acetylcholine receptors.
Keywords: Gosha-jinki-gan, Platelet aggregation, Nitric oxide